LOS ANGELES CAPITAL MANAGEMENT LLC

Position in RYTM — Rhythm Pharmaceuticals, Inc.

CIK 1177206 LOS ANGELES, CA

Position in RYTM

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$1,736,620

+$934,844 QoQ

Shares Held

15,641

+69.7% QoQ

Ownership

0.023%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#137

of 299 holders

Holding Since

Sep 2020

9 quarters on record

Voting authority Sole 11% Shared 0% None 89%

Healthcare · as of Jun 30, 2026

LOS ANGELES CAPITAL MANAGEMENT LLC holds $888,562,834 across 167 Biotechnology names. RYTM ranks #25 (0.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	729,635	$219,642,024
2	HALO	Halozyme Therapeutics, Inc.	1,938,035	$151,689,999
3	CAI	Caris Life Sciences, Inc.	3,958,531	$70,541,022
4	INCY	Incyte Corp	578,986	$65,633,852
5	VRTX	Vertex Pharmaceuticals Inc / Ma	130,802	$64,973,277
6	EXEL	Exelixis, Inc.	1,159,457	$63,086,055
7	REGN	Regeneron Pharmaceuticals, Inc.	98,585	$61,471,690
8	RPRX	Royalty Pharma plc	877,674	$49,211,181

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,736,620	15,641	+69.7%	Shares	Sole	2026-08-13
2026-03-31	$801,776	9,219	-62.1%	Shares	Sole	2026-05-08
2025-12-31	$2,604,711	24,334	+45.5%	Shares	Sole	2026-02-11
2025-09-30	$1,688,653	16,721	+331.8%	Shares	Sole	2025-10-20
2025-06-30	$244,671	3,872	-63.4%	Shares	Sole	2025-08-07
2023-12-31	$486,960	10,593	-21.1%	Shares	Sole	2024-02-06
2023-09-30	$307,676	13,421	+10.7%	Shares	Sole	2023-11-06
2020-12-31	$360,595	12,129	-2.0%	Shares	Sole	2021-03-10
2020-09-30	$268,252	12,379	—	Shares	Sole	2020-11-02
No filing history on record for this holder in this stock.